CHICAGO, Dec. 4, 2025 /PRNewswire/ -- The MPN Research Foundation, a respected and influential member of the myeloproliferative neoplasms landscape, has two abstracts accepted for presentation at the ...
Multi-hit TP53 mutations are linked to poor survival in both MPN and AML, with median OS ranging from 4.8 to 11.6 months. Factors such as ASCT, pre-transplant therapy response, and concurrent TET2 or ...
The MPN Research Foundation, a respected and global influential member of the MPN landscape, has two abstracts accepted for the 67th American Society of Hematology (ASH) Annual Meeting and Exposition ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results